½ÃÀ庸°í¼­
»óǰÄÚµå
1514894

¼¼°èÀÇ IPV ¹é½Å ½ÃÀå : ºÎ¹®º°, ±¹°¡ ¹× Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)

IPV Vaccines Market, By Vaccine Type, By Age Group, By Distribution, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: AnalystView Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® 379 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

IPV ¹é½Å(IPV Vaccines) ½ÃÀå ±Ô¸ð´Â 2023³â 1¾ï 8,945¸¸ ´Þ·¯¿´À¸¸ç, 2024³âºÎÅÍ 2032³â±îÁö CAGR 8.3%·Î ÃßÀÌÇϸç È®´ë ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

IPV ¹é½Å ½ÃÀå-½ÃÀå ¿ªÇÐ

¿¹¹æ Á¢Á¾ ÇÁ·Î±×·¥¿¡ ´ëÇÑ Á¤ºÎ ÀÚ±Ý Áõ°¡´Â IPV ¹é½Å äÅÃÀ» ÃËÁø

¿¹¹æ Á¢Á¾ ÇÁ·Î±×·¥¿¡ ´ëÇÑ Á¤ºÎ ÀÚ±Ý Áõ°¡´Â IPV ¹é½Å äÅÃÀ» Å©°Ô µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2020³â ¼¼°èº¸°Ç±â±¸(WHO)´Â ¹é½ÅÁ¢Á¾ °­È­·Î ¼¼°è ¼Ò¾Æ¸¶ºñ ȯÀÚ°¡ 90% °¨¼ÒÇß´Ù°í º¸°íÇß½À´Ï´Ù. °Ô´Ù°¡ ¹Ì±¹ Á¤ºÎ´Â 2021³â 2¾ï 3,700¸¸ ´Þ·¯¸¦ ¼Ò¾Æ¸¶ºñ ¹Ú¸ê Ȱµ¿¿¡ ÇÒ´çÇϰí IPV ¹é½ÅÀÇ º¸±Þ¿¡ Á¾»çÇÏ´Â ÀÚ¼¼¸¦ ´õ¿í °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾öû³­ ÅõÀÚ´Â IPV ¹é½ÅÀÇ °¡¿ë¼º°ú °¡¿ë¼ºÀ» º¸ÀåÇÏ°í ±Ã±ØÀûÀ¸·Î ¿¹¹æ Á¢Á¾·üÀ» Çâ»ó½ÃŰ°í ¼¼°è ¼Ò¾Æ¸¶ºñ ¹Ú¸êÀÇ ¸ñÇ¥¸¦ Çö½Ç¿¡ °¡±õ°Ô ¸¸µå´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

IPV ¹é½Å ½ÃÀå-ÁÖ¿ä ÀλçÀÌÆ®

¿ì¸® ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ® ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â)¿¡ ¾à 8.3%ÀÇ CAGR·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹é½Å À¯Çüº°·Î IPV ¹é½ÅÀº 2023³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸¿©ÁÙ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¬·ÉÃþº°·Î´Â 2023³â¿¡ ¼Ò¾Æ°ú°¡ ÁÖ¿ä À¯ÇüÀ̾ú½À´Ï´Ù.

À¯Å뺰·Î´Â 2023³â¿¡´Â °øÀû ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ÀÌ ÁÖ¿ä À¯ÇüÀ̾ú½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ÁÖ¿ä ¼öÀÍ¿øÀ̾ú½À´Ï´Ù.

IPV ¹é½Å ½ÃÀå-¼¼ºÐÈ­ ºÐ¼® :

¼¼°è IPV ¹é½Å ½ÃÀåÀº ¹é½Å À¯Çü, ¿¬·ÉÃþ, À¯Åë, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº ¹é½Å À¯Çü¿¡ ÀÇÇØ 2°¡Áö·Î ºÐ·ùµË´Ï´Ù : ºÒȰ¼ºÈ­ Æú¸®¿À¹ÙÀÌ·¯½º ¹é½Å(Inactivated Poliovirus Vaccine)°ú °æ±¸ Æú¸®¿À¹ÙÀÌ·¯½º ¹é½Å(Oral Poliovirus Vaccine)ÀÔ´Ï´Ù. ºÒȰ¼ºÈ­µÈ Æú¸®¿À¹ÙÀÌ·¯½º ¹é½Å ½ÃÀåÀº °æ±¸ Æú¸®¿À¹ÙÀÌ·¯½º ¹é½Åº¸´Ù ¾ÈÀü¼ºÀÌ ³ô°í, Á¤ºÎÀÇ °­·ÂÇÑ Áö¿ø°ú IPV ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥À» ÅëÇØ ¼Ò¾Æ¸¶ºñ ¹Ú¸êÀ» ¸ñÇ¥·Î ÇÏ´Â ±¹Á¦ÀûÀÎ ³ë·ÂÀÌ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº ¿¬·ÉÃþº°·Î µÎ °¡Áö ¹üÁÖ·Î ºÐ·ùµË´Ï´Ù. ¼Ò¾Æ¿ë ¹× ¼ºÀοë. ¼Ò¾Æ°ú ºÐ¾ß°¡ °¡Àå ³ôÀº Á¡À¯À²À» Â÷ÁöÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀÇ·á Áöħ¿¡ µû¶ó Àǹ«È­µÇ°í Á¤ºÎ ¹× ±¹Á¦Àû ³ë·Â¿¡ ÀÇÇØ Áö¿øµÇ´Â ¾î¸° ½ÃÀý ¼Ò¾Æ¸¶ºñ¸¦ ¿¹¹æÇϱâÀ§ÇÑ ¼Ò¾Æ¸¦ ´ë»óÀ¸·Î ÇÑ ¼¼°è ¿¹¹æ Á¢Á¾ ÇÁ·Î±×·¥¿¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù.

IPV ¹é½Å ½ÃÀå-Áö¿ªº° ÅëÂû·Â

ºÏ¹Ì¿¡¼­´Â Á¤ºÎÀÇ °­·ÂÇÑ Áö¿ø°ú °ß°íÇÑ °Ç°­ °ü¸® ½Ã½ºÅÛÀÌ IPV ¹é½ÅÀÇ ³ôÀº º¸±Þ·üÀ» º¸ÀåÇÕ´Ï´Ù. À¯·´Àº Á¾ÇÕÀûÀÎ ¿¹¹æ Á¢Á¾ ÇÁ·Î±×·¥°ú À¯·´ ¹é½Å Çൿ °èȹ°ú °°Àº ÀÌ´Ï¼ÅÆ¼ºê¸¦ ¹è°æÀ¸·Î Å« Á¸Àç°¨À» º¸¿©ÁÝ´Ï´Ù. ¾Æ½Ã¾Æ ÅÂÆò¾ç, ƯÈ÷ Àεµ¿Í Áß±¹Àº Àα¸°¡ ¸¹°í WHO¿Í À¯´Ï¼¼ÇÁ °°Àº ±¹Á¦±â±¸¿Í Á¤ºÎ°¡ Àû±ØÀûÀ¸·Î ¼Ò¾Æ¸¶ºñ ¹Ú¸ê Ä·ÆäÀÎÀ» ÆîÄ¡°í Àֱ⠶§¹®¿¡ ±Þ¼ÓÈ÷ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¼Ò¾Æ¸¶ºñ À¯ÇàÀÌ °¡Àå ³ôÀº ¾ÆÇÁ¸®Ä«¿¡¼­´Â ÀÎÇÁ¶ó Á¦¾àÀ¸·Î ÀÎÇÑ °úÁ¦´Â ³²¾Æ ÀÖÀ¸¸ç ¼¼°è º¸°Ç±â±¸°¡ ÀÚ±ÝÀ» Á¦°øÇϰí IPV ¹é½Å ¹èÆ÷¿¡ ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ³²¹Ì¿¡¼­´Â Áö¿ª ¿¹¹æ Á¢Á¾ ÃßÁø°ú °Ç°­ °ü¸® ¾×¼¼½º °³¼±ÀÌ ½ÃÀåÀÇ ²ÙÁØÇÑ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

IPV ¹é½Å ½ÃÀå-°æÀï ±¸µµ :

IPV ¹é½Å ½ÃÀåÀº Çõ½Å, Àü·«Àû Á¦ÈÞ, ±¤¹üÀ§ÇÑ À¯Åë¸ÁÀ» ÅëÇØ ½ÃÀå Á¡À¯À² È®´ë¸¦ ¸ñÇ¥·Î ÇÏ´Â ÁÖ¿ä Á¦¾à ±â¾÷ °£ÀÇ °Ý·ÄÇÑ °æÀïÀÌ Æ¯Â¡ÀÔ´Ï´Ù. Sanofi Pasteur, GlaxoSmithKline, Pfizer µî ´ëÇü Á¦¾à ±â¾÷ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, ±¤¹üÀ§ÇÑ Á¶»ç °³¹ß ´É·Â°ú ¼¼°èÀûÀÎ µµ´Þ¹üÀ§¸¦ Ȱ¿ëÇÏ¿© È¿°úÀûÀÌ°í ¾ÈÀüÇÑ IPV ¹é½ÅÀ» ½ÃÀå¿¡ ÅõÀÔÇϰí ÀÖ´Ù ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷µéÀº ´ë±Ô¸ð ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥À» Áö¿øÇϱâ À§ÇØ Á¤ºÎ ±â°ü ¹× WHO ¹× À¯´Ï¼¼ÇÁ¿Í °°Àº ±¹Á¦ º¸°Ç±â±¸¿Í ÀÚÁÖ ÆÄÆ®³Ê½ÊÀ» ¸Î°í ÀÖ½À´Ï´Ù. ½ÅÈï±â¾÷°ú Áö¿ª Á¦Á¶¾÷üµµ ¼ö¿ä Áõ°¡¿Í Á¤ºÎ Áö¿ø Á¤Ã¥¿¡ ÈûÀÔ¾î ½ÃÀå¿¡ ÁøÃâÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ º¸Á¸¹æ¹ýÀÇ °³¼±À̳ª È¥ÇÕ¹é½ÅÀÇ °³¹ß µî ¹é½Å±â¼úÀÇ Áøº¸¿¡ ÀÇÇØ °æÀïÀÌ °ÝÈ­µÇ°í ÀÖ¾î °¢»ç´Â Á¦°øÇÏ´Â Á¦Ç°ÀÇ Â÷º°È­¸¦ µµ¸ðÇØ ¼±Áø±¹¡¤°³¹ßµµ»ó±¹ ¾çÂÊ¿¡¼­ ÇÁ·¹Á𽺸¦ È®´ëÇÏ·Á°í Çϰí ÀÖ´Ù ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå IPV ¹é½Å ½ÃÀå °³¿ä

  • Á¶»ç ¹üÀ§
  • ½ÃÀå ÃßÁ¤ ¿¬µµ

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ºÐ¼®
  • °æÀï ÀλçÀÌÆ®

Á¦3Àå IPV ¹é½ÅÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ½ÃÀåÀÇ ¹Ì·¡ µ¿Çâ

Á¦4Àå IPV ¹é½Å »ê¾÷ Á¶»ç

  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ¼ºÀå Àü¸Á ¸ÊÇÎ
  • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© ºÐ¼®

Á¦5Àå IPV ¹é½Å ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

  • COVID-19 ÀÌÀüÀÇ ¿µÇ⠺м®
  • COVID-19 ÀÌÈÄÀÇ ¿µÇ⠺м®

Á¦6Àå IPV ¹é½Å ½ÃÀå »óȲ

  • IPV ¹é½Å ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • ÁÖ¿ä Á¦Á¶¾÷üº° ºÐ¼® µ¥ÀÌÅÍ
    • ±âÁ¸ ±â¾÷ ºÐ¼®
    • ½ÅÈï±â¾÷ ºÐ¼®

Á¦7Àå IPV ¹é½Å ½ÃÀå-¹é½Å À¯Çüº°

  • °³¿ä
    • ¹é½Å À¯Çüº° ºÎ¹® Á¡À¯À² ºÐ¼®
    • ºÒȰ¼ºÈ­ Æú¸®¿À¹ÙÀÌ·¯½º ¹é½Å(IPV)
    • °æ±¸ Æú¸®¿À¹ÙÀÌ·¯½º ¹é½Å(OPV)

Á¦8Àå IPV ¹é½Å ½ÃÀå-¿¬·ÉÃþº°

  • °³¿ä
    • ¿¬·ÉÃþº° ºÎ¹® Á¡À¯À² ºÐ¼®
    • ¼Ò¾Æ
    • ¼ºÀÎ

Á¦9Àå IPV ¹é½Å ½ÃÀå-À¯Å뺰

  • °³¿ä
    • À¯Å뺰 ºÎ¹® Á¡À¯À² ºÐ¼®
    • °øÁß ¿¹¹æ Á¢Á¾ ÇÁ·Î±×·¥
    • ¹Î°£ ¿¹¹æÁ¢Á¾ Ŭ¸®´Ð
    • ¾à±¹
    • ¿Â¶óÀÎ ¾à±¹

Á¦10Àå IPV ¹é½Å ½ÃÀå-ÃÖÁ¾ »ç¿ëÀÚº°

  • °³¿ä
    • ÃÖÁ¾ »ç¿ëÀÚº° ºÎ¹® Á¡À¯À² ºÐ¼®
    • º´¿ø
    • Ŭ¸®´Ð
    • °øÁßÀ§»ý±â°ü
    • ±âŸ

Á¦11Àå IPV ¹é½Å ½ÃÀå-Áö¿ªº°

  • ¼Ò°³
  • ºÏ¹Ì
    • °³¿ä
    • ºÏ¹ÌÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • °³¿ä
    • À¯·´ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ·¯½Ã¾Æ
    • ³×´ú¶õµå
    • ½º¿þµ§
    • Æú¶õµå
    • ±âŸ
  • ¾Æ½Ã¾Æ ÅÂÆò¾ç
    • °³¿ä
    • ¾Æ½Ã¾Æ ÅÂÆò¾çÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
    • Àεµ
    • Áß±¹
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • ű¹
    • Àεµ³×½Ã¾Æ
    • Çʸ®ÇÉ
    • ±âŸ
  • ³²¹Ì
    • °³¿ä
    • ³²¹ÌÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ÄÝ·Òºñ¾Æ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • °³¿ä
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ÅÍŰ
    • ¾ËÁ¦¸®
    • ÀÌÁýÆ®
    • ±âŸ

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼®-IPV ¹é½Å »ê¾÷

  • °æÀï ´ë½Ãº¸µå
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Sanofi Pasteur
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Merck &Co., Inc.
    • Johnson &Johnson
    • Serum Institute of India Pvt. Ltd.
    • Bharat Biotech
    • Panacea Biotec Ltd.
    • Bio Farma
    • Sinovac Biotech Ltd.
    • Astellas Pharma Inc.
    • Sinopharm Group Co., Ltd.
    • Valneva SE
    • Innovax
    • LG Chem
    • PT Bio Farma(Persero)
    • ±âŸ

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

LYJ

REPORT HIGHLIGHT

IPV Vaccines Market size was valued at USD 189.45 million in 2023, expanding at a CAGR of 8.3% from 2024 to 2032.

The IPV Vaccines Market, defined as the sector dedicated to inactivated poliovirus vaccines used for polio prevention, is experiencing growth driven by global immunization initiatives and increasing awareness of polio eradication. The robust government vaccination programs, support from organizations like WHO and UNICEF, and rising incidences of polio in certain regions are propelling the market demand. However, market growth is restrained by the high costs of vaccine development and distribution challenges in remote areas. Nonetheless, opportunities exist in the development of combination vaccines, advancements in vaccine storage and delivery technologies, and increasing investments in healthcare infrastructure in emerging economies.

IPV Vaccines Market- Market Dynamics

Increased Government Funding for Immunization Programs Fuels Adoption of IPV Vaccines

Increased government funding for immunization programs is significantly boosting the adoption of IPV vaccines, as evidenced by initiatives. For instance, in 2020, the World Health Organization (WHO) reported a 90% reduction in polio cases worldwide due to enhanced vaccination efforts. Additionally, the U.S. government allocated USD 237 million to polio eradication efforts in 2021, further emphasizing the commitment to widespread IPV vaccine distribution. These substantial investments are crucial in ensuring the availability and accessibility of IPV vaccines, ultimately driving higher immunization rates and bringing the goal of global polio eradication closer to reality.

IPV Vaccines Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.3% over the forecast period (2024-2032)

Based on Vaccine Type segmentation, IPV vaccines were predicted to show maximum market share in the year 2023

Based on Age Group segmentation, Pediatrics was the leading type in 2023

Based on distribution segmentation, Public Vaccination Programs were the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

IPV Vaccines Market- Segmentation Analysis:

The Global IPV vaccine market is segmented based on Vaccine Type, Age Group, Distribution, End-User, and Region.

The market is divided into two categories based on Vaccine Type: Inactivated Poliovirus Vaccine, and Oral Poliovirus Vaccine. The Inactivated Poliovirus Vaccine segment led the market, driven by its enhanced safety profile compared to the Oral Poliovirus Vaccine, alongside strong government support and international efforts aimed at polio eradication through IPV immunization programs.

The market is divided into two categories based on Age Group: Pediatrics, and Adults. The pediatrics segment holds the highest share, driven by global immunization programs targeting children to prevent polio from an early age, as mandated by healthcare guidelines and supported by extensive government and international initiatives.

IPV Vaccines Market- Geographical Insights

In North America, strong government support and robust healthcare systems ensure high adoption rates of IPV vaccines. Europe also demonstrates a significant market presence, driven by comprehensive immunization programs and initiatives like the European Vaccine Action Plan. Asia-Pacific, particularly India and China, represents a rapidly expanding segment due to large populations and aggressive polio eradication campaigns supported by both governments and international organizations like WHO and UNICEF. Africa, facing the highest polio prevalence, sees substantial efforts in IPV vaccine distribution funded by global health organizations, although challenges remain due to infrastructural limitations. Latin America shows steady market growth fueled by regional immunization drives and improving healthcare access.

IPV Vaccines Market- Competitive Landscape:

The IPV vaccine market is characterized by strong competition among leading pharmaceutical companies, each striving to enhance their market share through innovation, strategic alliances, and extensive distribution networks. Major players such as Sanofi Pasteur, GlaxoSmithKline, and Pfizer dominate the market, leveraging their extensive R&D capabilities and global reach to introduce effective and safe IPV vaccines. These companies frequently engage in partnerships with government bodies and global health organizations like WHO and UNICEF to support large-scale immunization programs. Emerging players and regional manufacturers are also entering the market, driven by increasing demand and supportive governmental policies. Additionally, advancements in vaccine technology, such as improved storage solutions and combination vaccines, are intensifying competition as companies seek to differentiate their offerings and expand their presence in both developed and developing regions.

Recent Developments:

In December 2023, Panacea Biotec launched EasyFourPol, a fully liquid pentavalent vaccine in India, safeguarding children against diphtheria, tetanus, pertussis, polio, and Haemophilus influenza type B infections.

In April 2024, The Business Standard announced India's capability to supply its entire IPV within 3-4 months, emphasizing the necessity of additional doses to sustain the nation's polio-free status. Sanofi and Serum Institute of India (SII) are identified as the primary IPV vaccine suppliers, with Sanofi contributing approximately 80% of the requirement.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL IPV VACCINES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Sanofi Pasteur

GlaxoSmithKline plc

Pfizer Inc.

Merck & Co., Inc.

Johnson & Johnson

Serum Institute of India Pvt. Ltd.

Bharat Biotech

Panacea Biotec Ltd.

Bio Farma

Sinovac Biotech Ltd.

Astellas Pharma Inc.

Sinopharm Group Co., Ltd.

Valneva SE

Innovax

LG Chem

PT Bio Farma (Persero)

Others

GLOBAL IPV VACCINES MARKET, BY VACCINE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Inactivated Poliovirus Vaccine (IPV)
  • Oral Poliovirus Vaccine (OPV)

GLOBAL IPV VACCINES MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019 - 2032

  • Pediatrics
  • Adults

GLOBAL IPV VACCINES MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

  • Public Vaccination Programs
  • Private Vaccination Clinics
  • Pharmacies
  • Online Pharmacies

GLOBAL IPV VACCINES MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Public Health Agencies
  • Others

GLOBAL IPV VACCINES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. IPV Vaccines Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. IPV Vaccines Market Snippet by Vaccine Type
    • 2.1.2. IPV Vaccines Market Snippet by Age Group
    • 2.1.3. IPV Vaccines Market Snippet by Distribution
    • 2.1.4. IPV Vaccines Market Snippet by End-User
    • 2.1.5. IPV Vaccines Market Snippet by Country
    • 2.1.6. IPV Vaccines Market Snippet by Region
  • 2.2. Competitive Insights

3. IPV Vaccines Key Market Trends

  • 3.1. IPV Vaccines Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. IPV Vaccines Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. IPV Vaccines Market Opportunities
  • 3.4. IPV Vaccines Market Future Trends

4. IPV Vaccines Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. IPV Vaccines Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. IPV Vaccines Market Landscape

  • 6.1. IPV Vaccines Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. IPV Vaccines Market - By Vaccine Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Vaccine Type, 2023 & 2032 (%)
    • 7.1.2. Inactivated Poliovirus Vaccine (IPV)
    • 7.1.3. Oral Poliovirus Vaccine (OPV)

8. IPV Vaccines Market - By Age Group

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Age Group, 2023 & 2032 (%)
    • 8.1.2. Pediatrics
    • 8.1.3. Adults

9. IPV Vaccines Market - By Distribution

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution, 2023 & 2032 (%)
    • 9.1.2. Public Vaccination Programs
    • 9.1.3. Private Vaccination Clinics
    • 9.1.4. Pharmacies
    • 9.1.5. Online Pharmacies

10. IPV Vaccines Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Clinics
    • 10.1.4. Public Health Agencies
    • 10.1.5. Others

11. IPV Vaccines Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. IPV Vaccines Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. IPV Vaccines Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. IPV Vaccines Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. IPV Vaccines Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. IPV Vaccines Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- IPV Vaccines Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Sanofi Pasteur
    • 12.2.2. GlaxoSmithKline plc
    • 12.2.3. Pfizer Inc.
    • 12.2.4. Merck & Co., Inc.
    • 12.2.5. Johnson & Johnson
    • 12.2.6. Serum Institute of India Pvt. Ltd.
    • 12.2.7. Bharat Biotech
    • 12.2.8. Panacea Biotec Ltd.
    • 12.2.9. Bio Farma
    • 12.2.10. Sinovac Biotech Ltd.
    • 12.2.11. Astellas Pharma Inc.
    • 12.2.12. Sinopharm Group Co., Ltd.
    • 12.2.13. Valneva SE
    • 12.2.14. Innovax
    • 12.2.15. LG Chem
    • 12.2.16. PT Bio Farma (Persero)
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦